Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal
cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not
responded to chemotherapy, surgery or radiation therapy.
PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015
immunotoxin in treating patients who have Non-Hodgkin's lymphoma and do not respond to
treatment.